Semin Thromb Hemost 2020; 46(02): 189-198
DOI: 10.1055/s-0039-1701016
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Temporal Changes in Fibrinolysis following Injury

Hunter B. Moore
1   Division of Transplant Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado
,
Ernest E. Moore
1   Division of Transplant Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado
2   Department of Surgery, Ernest E. Moore Shock and Trauma Center at Denver Health, Denver, Colorado
› Author Affiliations
Funding This study was supported in part by National Institute of General Medical Sciences (NIGMS; grant no. T32-GM008315) and the National Heart Lung and Blood Institute (NHLBI; grant no. 1UM1HL120877).
Further Information

Publication History

Publication Date:
11 March 2020 (online)

Abstract

Trauma patients present to the emergency department with a spectrum of fibrinolytic activity. This wide variance in fibrinolysis activity is a complex multifactorial process impacted by the degree of hemorrhagic shock and the amount of tissue injury the individual sustains. The fibrinolytic activity of the trauma patient at presentation to the hospital has prognostic and therapeutic implications. Those patients with high fibrinolytic activity (hyperfibrinolysis) are at risk of mortality from hemorrhage, whereas those patients with low fibrinolytic activity (shutdown or hypofibrinolysis) are at an increased risk of delayed mortality from traumatic brain injury or organ failure. These phenotypes of fibrinolysis acutely following injury change with resuscitation, and the majority of trauma patients will transition to a fibrinolytic resistant state several hours after injury. The mechanism for this near-global transition to this acquired fibrinolysis appears to be related to the generation of plasminogen activator inhibitor-1 in the liver. Those patients who do not recover from this fibrinolytic state 24 hours after injury have a poor prognosis. The purpose of this article is to review the different states of fibrinolytic activity following injury and how they change over time following resuscitation and in the intensive care unit.

 
  • References

  • 1 Moore HB, Moore EE, Gonzalez E. , et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77 (06) 811-817 , discussion 817
  • 2 Innes D, Sevitt S. Coagulation and fibrinolysis in injured patients. J Clin Pathol 1964; 17: 1-13
  • 3 Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. Persistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients. J Am Coll Surg 2017; 224 (04) 575-582
  • 4 Moore HB, Moore EE, Neal MD. , et al. Fibrinolysis shutdown in trauma: historical review and clinical implications. Anesth Analg 2019; 129 (03) 762-773
  • 5 Schöchl H, Frietsch T, Pavelka M, Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67 (01) 125-131
  • 6 Moore HB, Gonzalez E, Huebner BJ. , et al. Reperfusion shutdown: delayed onset of fibrinolysis resistance after resuscitation from hemorrhagic shock is associated with increased circulating levels of plasminogen activator inhibitor-1 and postinjury complications. Blood 2016; 128: 206
  • 7 Chakrabarti R, Hocking ED, Fearnley GR. Reaction pattern to three stresses--electroplexy, surgery, and myocardial infarction--of fibrinolysis and plasma fibrinogen. J Clin Pathol 1969; 22 (06) 659-662
  • 8 Kashuk JL, Moore EE, Sawyer M. , et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010; 252 (03) 434-442 , discussion 443–444
  • 9 Cotton BA, Harvin JA, Kostousouv V. , et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 2012; 73 (02) 365-370 , discussion 370
  • 10 Cardenas JC, Wade CE, Cotton BA. , et al; PROPPR Study Group. TEG lysis shutdown represents coagulopathy in bleeding trauma patients: analysis of the PROPPR cohort. Shock 2019; 51 (03) 273-283
  • 11 Moore HB, Moore EE, Chapman MP. , et al. Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial. Lancet 2018; 392 (10144): 283-291
  • 12 Moore HB, Moore EE, Liras IN. , et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 2016; 222 (04) 347-355
  • 13 Gall LS, Vulliamy P, Gillespie S. , et al; Targeted Action for Curing Trauma-Induced Coagulopathy (TACTIC) partners. The S100A10 pathway mediates an occult hyperfibrinolytic subtype in trauma patients. Ann Surg 2019; 269 (06) 1184-1191
  • 14 MacFarlane RG, Biggs R. Fibrinolysis; its mechanism and significance. Blood 1948; 3 (10) 1167-1187
  • 15 William Hewson.. Of the causes of the inflammatory crust's appearing at different times in bloodletting; of the stopping of hemorrhages; and of the effects of cold upon the blood. In: Gulliver G. , ed. The Works of William Hewson, F.R.S. London: C and J Adlard Printers; 1772: 42-52
  • 16 Cannon WB, Gray H. Factors affecting the coagulation time of blood. Am J Physiol 1914; 34: 232-242
  • 17 Crowell JW, Read WL. In vivo coagulation; a probable cause of irreversible shock. Am J Physiol 1955; 183 (03) 565-569
  • 18 Turpini R, Stefanini M. The nature and mechanism of the hemostatic breakdown in the course of experimental hemorrhagic shock. J Clin Invest 1959; 38 (1, Part 1): 53-65
  • 19 Hardaway RM, Brune WH, Geever EF, Burns JW, Mock HP. Studies on the role of intravascular coagulation in irreversible hemorrhagic shock. Ann Surg 1962; 155: 241-250
  • 20 Hardaway RM, Burns JW. Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock. Ann Surg 1963; 157: 305-309
  • 21 Hardaway III RM, McKay DG. Disseminated intravascular coagulation: a cause of shock. Ann Surg 1959; 149 (04) 462-470
  • 22 Hardaway RM. Disseminated intravascular coagulation with special reference to shock and its treatment. Mil Med 1965; 130: 451-460
  • 23 Wada H, Tanigawa M, Takagi M. , et al. Hemostatic changes before and after the onset of disseminated intravascular coagulation [in Japanese]. Rinsho Ketsueki 1989; 30 (10) 1755-1762
  • 24 Whaun JM, Oski FA, Urmson J. Experience with disseminated intravascular coagulation in a children's hospital. Can Med Assoc J 1972; 107 (10) 963-967
  • 25 Al-Mondhiry H. Disseminated intravascular coagulation: experience in a major cancer center. Thromb Diath Haemorrh 1975; 34 (01) 181-193
  • 26 Rytel MW, Dee TH, Ferstenfeld JE, Hensley GT. Possible pathogenetic role of capsular antigens in fulminant pneumococcal disease with disseminated intravascular coagulation (DIC). Am J Med 1974; 57 (06) 889-896
  • 27 Thachil J. The Elusive diagnosis of disseminated intravascular coagulation: does a diagnosis of DIC exist anymore?. Semin Thromb Hemost 2019; 45 (01) 100-107
  • 28 Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?. Ann Surg 2007; 245 (05) 812-818
  • 29 Chesebro BB, Rahn P, Carles M. , et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 2009; 32 (06) 659-665
  • 30 Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningsson P, Waisman DM. Regulation of fibrinolysis by S100A10 in vivo. Blood 2011; 118 (11) 3172-3181
  • 31 Sawamura A, Hayakawa M, Gando S. , et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res 2009; 124 (05) 608-613
  • 32 Oshiro A, Yanagida Y, Gando S, Henzan N, Takahashi I, Makise H. Hemostasis during the early stages of trauma: comparison with disseminated intravascular coagulation. Crit Care 2014; 18 (02) R61
  • 33 McKay DG. Clinical significance of intravascular coagulation. Bibl Haematol 1983; (49) 63-78
  • 34 Rühl H, Berens C, Winterhagen A, Müller J, Oldenburg J, Pötzsch B. Label-free kinetic studies of hemostasis-related biomarkers including D-dimer using autologous serum transfusion. PLoS One 2015; 10 (12) e0145012
  • 35 Nieuwenhuizen W. Fibrin-mediated plasminogen activation. Ann N Y Acad Sci 2001; 936: 237-246
  • 36 Samson AL, Knaupp AS, Sashindranath M. , et al. Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin. Cell Rep 2012; 2 (04) 889-901
  • 37 Walker CB, Moore EE, Kam A. , et al. Clot activators do not expedite the time to predict massive transfusion in trauma patients analyzed with tissue plasminogen activator thrombelastography. Surgery 2019; 166 (03) 408-415
  • 38 Petäjä J, Rasi V, Myllylä G, Vahtera E, Hallman H. Familial hypofibrinolysis and venous thrombosis. Br J Haematol 1989; 71 (03) 393-398
  • 39 Nguyen G, Horellou MH, Kruithof EK, Conard J, Samama MM. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Blood 1988; 72 (02) 601-605
  • 40 Moore HB, Moore EE, Huebner BR. , et al. Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator. J Trauma Acute Care Surg 2017; 83 (06) 1014-1022
  • 41 Gomez-Builes JC, Acuna SA, Nascimento B, Madotto F, Rizoli SB. Harmful or physiologic: diagnosing fibrinolysis shutdown in a trauma cohort with rotational thromboelastometry. Anesth Analg 2018; 127 (04) 840-849
  • 42 Moore HB, Chapman MP, Hansen K. , et al. Elevated fibrin degradation products with low fibrinolytic activity measured by thromboelastographic in severely injured patients does not warrant tranexamic acid to improve clot strength. JACS 2019 (e-pub ahead of print)
  • 43 Beer J, Coller BS. Evidence that platelet glycoprotein IIIa has a large disulfide-bonded loop that is susceptible to proteolytic cleavage. J Biol Chem 1989; 264 (29) 17564-17573
  • 44 Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg 2001; 67 (04) 377-382
  • 45 Kluft C, Verheijen JH, Jie AF. , et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45 (07) 605-610
  • 46 Otter M, Kuiper J, van Berkel TJ, Rijken DC. Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver. Ann N Y Acad Sci 1992; 667: 431-442
  • 47 de Boer A, Kluft C, Kroon JM. , et al. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost 1992; 67 (01) 83-87
  • 48 Moore HB, Moore EE, Lawson PJ. , et al. Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock. Surgery 2015; 158 (02) 386-392
  • 49 Macko AR, Moore HB, Cap AP, Meledeo MA, Moore EE, Sheppard FR. Tissue injury suppresses fibrinolysis after hemorrhagic shock in nonhuman primates (rhesus macaque). J Trauma Acute Care Surg 2017; 82 (04) 750-757
  • 50 Prat NJ, Montgomery R, Cap AP. , et al. Comprehensive evaluation of coagulation in swine subjected to isolated primary blast injury. Shock 2015; 43 (06) 598-603
  • 51 Reust DL, Reeves ST, Abernathy III JH. , et al. Temporally and regionally disparate differences in plasmin activity by tranexamic acid. Anesth Analg 2010; 110 (03) 694-701
  • 52 Jern C, Seeman-Lodding H, Biber B, Winsö O, Jern S. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig. Thromb Haemost 1997; 78 (03) 1150-1156
  • 53 Kassam G, Choi KS, Ghuman J. , et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998; 273 (08) 4790-4799
  • 54 Kassam G, Le BH, Choi KS. , et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry 1998; 37 (48) 16958-16966
  • 55 Macintyre IM, Webber RG, Crispin JR. , et al. Plasma fibrinolysis and postoperative deep vein thrombosis. Br J Surg 1976; 63 (09) 694-697
  • 56 Kassis J, Hirsh J, Podor TJ. Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. Blood 1992; 80 (07) 1758-1764
  • 57 Paganelli F, Alessi MC, Morange P, Maixent JM, Lévy S, Vague IJ. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost 1999; 82 (01) 104-108
  • 58 Roberts DJ, Kalkwarf KJ, Moore HB. , et al. Time course and outcomes associated with transient versus persistent fibrinolytic phenotypes after injury: a nested, prospective, multicenter cohort study. J Trauma Acute Care Surg 2019; 86 (02) 206-213
  • 59 Leeper CM, Neal MD, McKenna CJ, Gaines BA. Trending fibrinolytic dysregulation: fibrinolysis shutdown in the days after injury is associated with poor outcome in severely injured children. Ann Surg 2017; 266 (03) 508-515
  • 60 Roberts DJ, Kalkwarf KJ, Moore HB. , et al. Time course and outcomes associated with transient versus persistent fibrinolytic phenotypes after injury: a nested, prospective, multicenter cohort study. J Trauma Acute Care Surg 2019; 86 (02) 206-213
  • 61 Gall LS, Vulliamy P, Gillespie S. , et al; Targeted Action for Curing Trauma-Induced Coagulopathy (TACTIC) partners. The S100A10 pathway mediates an occult hyperfibrinolytic subtype in trauma patients. Ann Surg 2018 (e-pub ahead of print) Doi: 10.1097/SLA.0000000000002733
  • 62 Meizoso JP, Karcutskie CAT, Ray JJ, Namias N, Schulman CI, Proctor KG. Persistent fibrinolysis shutdown associated with increased mortality in severely injured trauma patients. J Am Coll Surg 2017; 224 (04) 575-582
  • 63 Huebner BR, Moore EE, Moore HB. , et al. Thrombin stimulates increased plasminogen activator inhibitor-1 release from liver compared to lung endothelium. J Surg Res 2018; 225: 1-5
  • 64 Fujii S, Lucore CL, Hopkins WE, Billadello JJ, Sobel BE. Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells. Thromb Haemost 1990; 64 (03) 412-419
  • 65 Villamediana LM, Rondeau E, He CJ. , et al. Thrombin regulates components of the fibrinolytic system in human mesangial cells. Kidney Int 1990; 38 (05) 956-961
  • 66 Raeven P, Salibasic A, Drechsler S. , et al. A non-lethal traumatic/hemorrhagic insult strongly modulates the compartment-specific PAI-1 response in the subsequent polymicrobial sepsis. PLoS One 2013; 8 (02) e55467
  • 67 Griemert EV, Schwarzmaier SM, Hummel R. , et al. Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury. Ann Neurol 2019; 85 (05) 667-680
  • 68 Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389: 39-48
  • 69 Brass LF, Stalker TJ. Minding the gaps--and the junctions, too. Circulation 2012; 125 (20) 2414-2416
  • 70 Moore HB, Moore EE, Gonzalez E. , et al. Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock 2015; 43 (01) 39-46
  • 71 Holcomb JB, Zarzabal LA, Michalek JE. , et al; Trauma Outcomes Group. Increased platelet:RBC ratios are associated with improved survival after massive transfusion. J Trauma 2011; 71 (02) (Suppl. 03) S318-S328
  • 72 Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen TE. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg 2013; 148 (03) 218-225
  • 73 He S, Johnsson H, Zabczyk M, Hultenby K, Wallén H, Blombäck M. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates. Thromb Haemost 2014; 111 (03) 417-428
  • 74 Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. Thromb Haemost 2014; 112 (04) 649-658
  • 75 Ramanathan A, Karuri N. Fibronectin alters the rate of formation and structure of the fibrin matrix. Biochem Biophys Res Commun 2014; 443 (02) 395-399
  • 76 Meizoso JP, Dudaryk R, Mulder MB. , et al. Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid. J Trauma Acute Care Surg 2018; 84 (03) 426-432
  • 77 Prakash S, Verghese S, Roxby D, Dixon D, Bihari S, Bersten A. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test--ROTEM. J Crit Care 2015; 30 (02) 264-270
  • 78 Barrett CD, Moore HB, Banerjee A, Silliman CC, Moore EE, Yaffe MB. Human neutrophil elastase mediates fibrinolysis shutdown through competitive degradation of plasminogen and generation of angiostatin. J Trauma Acute Care Surg 2017; 83 (06) 1053-1061
  • 79 Wada T, Gando S, Mizugaki A. , et al. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction. Thromb Res 2013; 132 (01) e64-e69
  • 80 Hayakawa M, Sawamura A, Gando S, Jesmin S, Naito S, Ieko M. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res 2012; 130 (06) 906-913
  • 81 Iba T, Levy JH, Thachil J, Wada H, Levi M. ; Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis. The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thromb Res 2019; 179: 11-14
  • 82 Cafferata HT, Aggeler PM, Robinson AJ, Blaisdell FW. Intravascular coagulation in the surgical patient: its significance and diagnosis. Am J Surg 1969; 118 (02) 281-291
  • 83 Hardaway RM. The significance of coagulative and thrombotic changes after haemorrhage and injury. J Clin Pathol Suppl (R Coll Pathol) 1970; 4: 110-120
  • 84 Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA 1970; 214 (12) 2163-2172